MEG3 and Cognitive impairment: On the other hand, it is noteworthy that lncRNA‐MEG3 could be identified as a novel therapeutic target and molecular biomarker for diabetes‐related cognitive impairments and hyperglycemia‐triggered neurotoxicity [13].